The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease

Neurology

Volumn 52, Issue 6, 1999, Pages 1158-1165

  Delacourte, A ^a   David, J P ^a   Sergeant, N ^a   Buee L ^a   Wattez, A ^a   Vermersch, P ^a   Ghozali, F ^c   Fallet Bianco, C ^c   Pasquier, F ^b   Lebert, F ^b   Petit, H ^b   Di Menza, C ^c  

^a INSERM   (France)

^b CHU and U   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; PAIRED HELICAL FILAMENT; PRIORITY JOURNAL;

EID: 0032894121     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.6.1158     Document Type: Article

References (37)

1. Delacourte A, Buée L. Normal and pathological tau proteins as factors for microtubule assembly. Int Rev Cytol 1997;171: 167-224.
2. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991;1:103-116.
3. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995;16:271-278.
4. Hyman BT, Trojanowski JQ. Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:1095-1097.
5. Selkoe DJ. Neuroscience - Alzheimer's disease: genotypes, phenotype, and treatments. Science 1997;275:630-631.
6. Beyreuther K, Masters CL. The ins and outs of amyloid-β. Nature 1997;389:677-678
7. Permanne B, Buée L, David JP, Fallet-Bianco C, Dimenza C, Delacourte A. Quantitation of Alzheimer's amyloid peptide and identification of related amyloid proteins by dot-blot immunoassay. Brain Res 1995;685:154-162.
8. Gravina SA, Ho LB, Eckman CB, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain - biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 1995;270: 7013-016.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive stade of patients for the clinician. J Psychiatr Res 1975;12:189-198.
10. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
11. Benton AL. Normative observations on neuropsychological test performance in old age. J Clin Neuropathol 1981;3:33-42.
12. American Psychiatric Association. DSM-III-R. Diagnostic and statistical manual of mental disorders, 3rd ed., revised. Washington, DC: 1987.
13. McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
14. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43: 250-260.
15. Lopez OL, Larumbe MR, Becker JT. Reliability of NINDS-AIREN clinical criteria for the diagnosis of vascular dementia. Neurology 1994;44:1240-1245.
16. Moroney JT, Bagiella E, Desmond DW, et al. Meta-analysis of the Hachinski ischemic score in pathologically verified dementias. Neurology 1997;49:1096-1105.
17. Buée-Scherrer V, Condamines V, Mourton-Gilles O, et al. AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Mol Brain Res 1996;39:79-88.
18. Mirra SS, Heyman A, Mckeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). 2. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
19. Sergeant N, David JP, Goedert M, et al. Two-dimensional characterization of PHF-tau from Alzheimer's disease: demonstration of an additional 74 kDa component and age-related biochemical modifications. J Neurochem 1997;69:834-844.
20. Vermersch P, Frigard B, Delacourte A. Mapping of neurofibrillary degeneration in Alzheimer's disease - evaluation of heterogeneity using the quantification of abnormal tau proteins. Acta Neuropathol 1992;85:48-54.
21. Goedert M, Spillantini MG, Jakes R, et al. Molecular dissection of the paired helical filament. Neurobiol Aging 1995;16: 325-334.
22. Delacourte A, Sergeant N, Wattez A, Gauvreau D, Robitaille Y. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 1998;43:193-204.
23. Duyckaerts C, Bennecib M, Grignon Y, et al. Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol Aging 1997;18:267-273.
24. Hof PR, Nimchinsky EA, Ungerleider LG, Morrison JH. Morphologic and neurochemical characteristics of corticocortical projections: emergence of circuit-specific features and relationships to degenerative changes in Alzheimer's disease. Research and perspectives in Alzheimer's disease. In: Hyman BT, Duyckaerts C, Christen Y, eds. Connections, cognition and Alzheimer's disease. Berlin: Springer-Verlag, 1997: 59-82.
25. Braak H, Braak E. Aspects of cortical destruction in Alzheimer's disease. Research and perspectives in Alzheimer's disease. In: Hyman BT, Duyckaerts C, Christen Y, eds. Connections, cognition and Alzheimer's disease. Berlin: Springer-Verlag, 1997:1-16.
26. Vermersch P, David JP, Frigard B, et al. Cortical, mapping of Alzheimer pathology in brains of aged nondemented subjects. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1035-1047.
27. Giannakopoulos P, Hof PR, Michel JP, Guimon J, Bouras C. Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Res Brain Res Rev 1997;25:217-245.
28. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997;278:412-419.
29. Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995;52:81-88.
30. Hof PR, Bierer LM, Perl DP, et al. Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia - regional and laminar distribution of neurofibrillary tangles and senile plaques. Arch Neurol 1992;49:946-953.
31. Consensus report of the working group on molecular and biochemical markers of Alzheimer's disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-116.
32. Hardy J. Amyloid, the presenilins and Alzheimer's disease. TINS 1997;20:154-159.
33. Alter CA, DiStefano PS. Neurotrophin trafficking by anterograde transport. TINS 1998;21:433-437.
34. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 1993;262:695-700.
35. Yang F, Sun X, Beech W, et al. Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. Am J Pathol 1998;152:379-389.
36. Bowen DM, Francis PT, Procter AW, et al. Treatment strategy for the corticocortical neuron pathology of Alzheimer's disease. Ann Neurol 1992;32:112.
37. Yamada K, Nitta A, Hasegawa T, et al. Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Behav Brain Res 1997;83:117-122.